ICBMT 2022

PS Current role and future direction of hematopoietic cell transplantation Mary Horowitz Medical College of Wisconsin, USA CV

PL01-1 Adoptive immunotherapy for hematologic malignancies Catherine Bollard George Washington University, USA CV

PL01-2 Dual targeting CAR T cell therapy David B. Miklos Stanford University, USA CV

PL02-1 Treatment for steroid-refractory acute GVHD Paul J. Martin Fred Hutchinson Cancer Center, USA CV

PL02-2 Treatment for steroid-refractory chronic GVHD Takanori Teshima Hokkaido University Hospital, Japan cv

SS01-1 Maintenance therapy in AML to prevent relapse after allogeneic HSCT Uwe Platzbecker Leipzig University Hospital, Germany cv

SS01-2 Management of Acute Leukemias Relapsing After the First Allogeneic HCT: A Second allogeneic HCT or DLI? Mohamed A. Kharfan-Dabaja Mayo Clinic, USA CV

SS01-3 Relapse prevention with TKI after allogeneic HSCT in Philadelphia positive ALL Nicola Gökbuget Goethe University, Germany CV

SS02-1 What to consider in donor selection with alternative donors Rupert Handgretinger Eberhard Karls University Tuebingen, Germany CV

SS02-2 Primary graft failure in pediatric non-malignant disease: An old but critical hurdle Troy Lund University of Minnesota, USA CV

SS02-3 New insights of overcoming poor graft function after allogeneic HSCT in hematologic malignancies Rajat Kumar Princess Margaret Cancer Center, Canada CV

SS03-1 TBD Eun Young Choi Seoul National University College of Medicine, Korea cv

SS03-2 Enhancing T cell regeneration after HSCT Van den Brink MR Memorial Sloan Kettering Cancer Center, USA CV

SS03-3 Genomics in HSCT: Improving transplant outcomes Myungshin Kim The Catholic University of Korea, Korea cv

SS04-1 Redefining the role of transplant for patients with T-cell lymphoma in the immunotherapy era Satoshi Yamasaki National Hospital Organization Kyushu Medical Center, Japan CV

SS04-2 TBD Tracy T Batchelor Massachusetts General Hospital Cancer Center and Harvard Medical School, USA cv

SS04-3 Future direction of consolidation or maintenance therapy in myeloma Philip L. McCarthy Roswell Park Cancer Institute, USA CV

SS04-4 TBD Sung-Soo Park The Catholic University of Korea, Korea cv

SS05-1 Optimal donor selection algorithm based on CIBMTR data Bronwen Shaw Medical College of Wisconsin, USA CV

SS05-2 Who to transplant in CR1? Integrating knowledge-bank approaches in daily practice Raphael Itzykson Hopital Saint-Louis, France CV

SS05-3 St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem Jinghui Zhang St. Jude Children’s Research Hospital, USA CV

SS06-1 “Off-the-shelf” allogeneic CAR T cells Sham Mailankody Memorial Sloan Kettering Cancer Center, USA CV

SS06-2 DC-based immunotherapy for myeloid malignancies Je-Jung Lee Chonnam National University Medical School CV

SS06-3 TBD Rizwan Romee Harvard Medical School, USA cv

SS07-1 Insights into the role of gut microbiota in HSCT: GVHD and infection Daniele Zama University of Bologna, Italy CV

SS07-2 Manipulation of microbiome in HSCT Edoardo Muratore University of Bologna, Italy CV

SS07-3 The potential role of gut microbiome in the Immunobiology of CAR-T cell therapy Christoph K. Stein-Thoeringer Deutsches Krebsforschungszentrum, Germay CV

SS08-1 Risk stratification of GVHD with clinical prediction system and novel biomarkers John E. Levine The Tisch Cancer Institute, Mount Sinai School of Medicine, USA CV

SS08-2 Updated strategies of GVHD prevention Ho Sup Lee Kosin University College of Medicine, Korea cv

SS08-3 Biology based novel treatment approaches of GVHD Tomomi Toubai Yamagata University, Japan CV

SS09-1 TBD Jae-Sook Ahn Chonnam National University College of Medicine, Korea cv

SS09-2 TBD Sebastian Giebel Maria Sklodowska-Curie Cancer Center, Poland cv

SS09-3 Impact of MDS genomics on post-transplant relapse Bhagirathbhai Dholaria Vanderbilt University Medical Center, USA CV

SS10-1 TBD Mattia Algeri Bambino Gesù Childrens’ Hospital, Italy cv

SS10-2 TBD Seungmin Hahn Yonsei University College of Medicine, Korea cv

SS10-3 Who should be considered to receive HSCT in pediatric CML? Nobuko Hijiya Columbia University Medical Center, USA CV

SS11-1 Illuminating Functional Heterogeneity of the Bone Marrow Microenvironment Anastasia N. Tikhonova University of Toronto, Canada CV

SS11-2 TBD Satu Mustjoki University of Helsinki, Finland cv

SS11-3 TBD Kwang Pyo Kim Department of Applied Chemistry, Kyung Hee University, Korea cv

JS01-1 TBI-containing conditioning regimens without ATG in adults with aplastic anemia undergoing CBT Nobuhiro Hiramoto Kobe City Medical Center General Hospital, Japan cv

JS01-2 Alternative donor HSCT for SAA in Korea Jae Wook Lee The Catholic University of Korea, Korea cv

JS01-3 Investigation of telomere length shortening in pediatric aplastic anemia and congenital bone marrow failure Atsushi Narita Nagoya University, Japan cv

JS01-4 Comparison of HSCT and TPO-RAs with IST in SAA Jun Ho Jang Sungkyunkwan University School of Medicine, Korea cv

JS02-1 Annalisa Ruggeri IRCCS San Raffaele Scientific Institute, Italy cv

JS02-2 Haplo-HCT vs other sources A. Mussetti Institut Català d’Oncologia, Spain CV

JS02-3 Graft manipulation strategies for haploidentical hematopoietic cell transplantation Ho Joon Im University of Ulsan College of Medicine, Korea cv

JS02-4 Haploidentical transplantation in myeloid maliagnancy: is it a just alternative option? Silvia Park The Catholic University of Korea, Korea cv

JS03-1 TBD Amy Dezern Johns Hopkins University, USA cv

JS03-2 TBD Youngil Koh Seoul National University College of Medicine, Korea cv

JS03-3 Clonal hematopoiesis and its effects on cellular therapies (CAR T-cell therapy outcomes) Kelly Bolton Washington University School of Medicine in St. Louis, USA CV

JS04-1 TBD Alok Srivastava Christian Medical College, India cv

JS04-2 Genome editing of immune cells using CRISPR/Cas9 Chan Hyuk Kim KAIST, Korea cv

JS04-3 Enhanced anti-tumor effects of glioblastoma-targeting CAR-T cells by CRISPR-Cas9 Jung Min Lee School of Life Science, Handong Global University cv